Skip to content

Stephen Krahling

2025 Presentation(s):

The presentation will begin In:

Days
Hours
Minutes
Abstract
Biological products must meet specifications defined by clinical studies. The product release model for vaccines details product specifications related to potency, stability, safety, and efficacy. The number of doses children receive in one administration of the product is highly variable based on manufacturing variability, stability, and shelf life. Changes to the vaccine product, including overfilling, are not detailed in the package insert and are granted regulatory approval prior to clinical safety testing. The product label is missing key information required for informed consent.
Speaker Bio:

Steve Krahling is a research scientist in the field of molecular and cell biology.  As a laboratory scientist at Penn State University, he published research on phospholipid membrane dynamics and cell recognition systems involved in immune regulation.  As a virologist in the Virus and Cell Biology Department at Merck, he was responsible for characterizing Merck’s live virus vaccines. In 2010, he was one of two relators to file a qui tam lawsuit for fraud related to the safety and efficacy of Merck’s MMR vaccine.

share this speaker:

Facebook
Twitter
LinkedIn
Email